17 January 2024
: Case report 
Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Unexpected drug reaction, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Xinyi Meng1CEF, Jingsong He1BC, Fei Cheng2BC, Hui Yan3BD, Chunting Zhu1DF, Xing Guo1DF, Yi Li1AB, Zhen Cai1AG, Donghua He1A*DOI: 10.12659/AJCR.942534
Am J Case Rep 2024; 25:e942534
Table 1. Laboratory test results during the clinical course.
| Main indicators | Status before treatment | Status post cycle 1 (Oct.02, 2021) | Status post cycle 2 (Nov. 04, 2021) | Status post cycle 3 (Dec. 03, 2021) | Status post cycle 4 (Jan. 04, 2022) | Status post cycle 5 (Feb. 08, 2022) | Status post cycle 6 (Mar. 15, 2022) |
|---|---|---|---|---|---|---|---|
| Free light chain κ (mg/L) | 55.3 | 7.3 | 3.8 | 11.5 | 8.1 | 5.6 | 3.7 |
| Free light chain λ (mg/L) | 17.7 | 13.8 | 7 | 6.8 | 14.9 | 11 | 10.8 |
| dFLC (mg/L) | 37.6 | −6.5 | −3.2 | 4.7 | −6.8 | −5.4 | −7.1 |
| Blood/urine protein electrophoresis | +/+ | +/+ | +/+ | +/− | −/− | −/− | −/− |
| ALP (U/L) | 405 | 453 | 298 | 356 | 543 | 222 | 101 |
| Total bilirubin (μmol/L) | 299.8 | 252.5 | 181.6 | 179.5 | 78.8 | 16.3 | 14.5 |
| NT-ProBNP (pg/ml) | 552 | 1163 | 3328 | 915 | 1658 | 1163 | 647 |
| BNP (pg/ml) | 170.2 | 152.9 | 640.9 | 378.4 | 333.6 | 252 | 163.9 |
| 24-h urine protein (mg/24 h) | 11999 | 554 | / | 521 | 366 | 145 | / |